Midregional Proadrenomedullin (MRproADM) Serum Levels in Critically Ill Patients Are Associated with Short-Term and Overall Mortality during a Two-Year Follow-Up
Table 4
Patient characteristics and comparison between survivors and nonsurvivors (ICU and overall survival).
Parameter
All patients
Survivor ICU
Nonsurvivor ICU
Survivors overall
Nonsurvivor overall
Number
203
160
43
113
79
Female, (%)
79 (38.9)
60 (37.5)
19 (44.2)
0.425
45 (39.8)
28 (35.4)
0.538
Age median, (range) (years)
64 (18-90)
62 (18-90)
71 (35-89)
0.002
60 (18-82)
69 (22-90)
<0.001
Charlson comorbitity index
2 (0-9)
2 (0-8)
3 (3-9)
0.001
2 (0-6)
3 (3-9)
<0.001
APACHE II score, median (range)
18 (2-43)
16 (2-40)
23 (5-43)
0.001
16 (3-40)
20 (5-43)
0.004
SOFA score, median (range)
9 (0-17)
7 (0-17)
12 (7-17)
<0.001
7 (0-17)
10 (3-17)
0.997
Mechanical ventilation, (%)
137 (68.2)
96 (60.8)
41 (95.3)
<0.001
68 (60.2)
62 (79.5)
0.005
Vasopressor demand, (%)
125 (61.5)
88 (55.0)
37 (86.0)
<0.001
60 (53.1)
58 (73.4)
0.004
ICU days, median (range)
7 (1-137)
7 (1-137)
7 (1-56)
<0.001
7 (1-137)
7 (1-66)
<0.001
Cystatin C, median (range) (mg/L)
1.5 (0.5-8.4)
1.4 (0.4-8.4)
1.9 (1.0-3.4)
0.182
1.3 (0.4-4.7)
1.7 (0.8-8.4)
0.073
CRP, median (range) (mg/dL)
103.5 (0-230)
92 (5-230)
118 (0-230)
0.158
84.5 (5-230)
121 (0-230)
0.064
Prothrombin time, median (range) (%)
70 (0-100)
71.3 (8-100)
69 (0-99)
0.170
74 (8-100)
69 (0-100)
0.110
Lactate, median (range) (mmol/L)
1.4 (0-19)
1.5 (0.5-10.3)
1.6 (0-19)
0.071
1.4 (0.4-10.3)
1.5 (0-19)
0.093
MRproADM day 1, median (range) (nmol/L)
1.48 (0.1-35.2)
2.2 (0.1-25.2)
3.6 (0.2-27.0)
0.017
2 (19.4-0.1)
3.2 (0.2-35.2)
0.006
For quantitative variables, median and range (in parenthesis) are given. Abbreviations: APACHE: acute physiology and chronic health evaluation; CRP: C-reactive protein; ICU: intensive care unit; MRproADM: midregional proadrenomedullin; SOFA: sequential organ failure assessment. Significance between sepsis and nonsepsis patients was assessed using the Mann–Whitney test, Fisher’s exact test, or chi-squared test, respectively.
